U.S. markets open in 26 minutes
  • S&P Futures

    4,243.00
    -2.75 (-0.06%)
     
  • Dow Futures

    34,410.00
    -52.00 (-0.15%)
     
  • Nasdaq Futures

    14,013.75
    +19.50 (+0.14%)
     
  • Russell 2000 Futures

    2,331.00
    +0.50 (+0.02%)
     
  • Crude Oil

    71.59
    +0.68 (+0.96%)
     
  • Gold

    1,846.50
    -33.10 (-1.76%)
     
  • Silver

    27.58
    -0.57 (-2.01%)
     
  • EUR/USD

    1.2127
    +0.0021 (+0.17%)
     
  • 10-Yr Bond

    1.4670
    +0.0050 (+0.34%)
     
  • Vix

    16.05
    -0.05 (-0.31%)
     
  • GBP/USD

    1.4118
    +0.0001 (+0.01%)
     
  • USD/JPY

    109.7810
    +0.1460 (+0.13%)
     
  • BTC-USD

    39,730.30
    +3,899.16 (+10.88%)
     
  • CMC Crypto 200

    985.71
    +43.89 (+4.66%)
     
  • FTSE 100

    7,141.54
    +7.48 (+0.10%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the BofA Securities 2021 Healthcare Conference. Management is scheduled to participate in a Fireside Chat on Thursday, May 13, 2021 at 4:15 pm ET.

To access the webcast and subsequent archived recording of the presentation, please visit "Events" in the "Investors" section of the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of preclinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005023/en/

Contacts

Investor Contact:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200